EA202092162A1 - Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака - Google Patents

Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака

Info

Publication number
EA202092162A1
EA202092162A1 EA202092162A EA202092162A EA202092162A1 EA 202092162 A1 EA202092162 A1 EA 202092162A1 EA 202092162 A EA202092162 A EA 202092162A EA 202092162 A EA202092162 A EA 202092162A EA 202092162 A1 EA202092162 A1 EA 202092162A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
autoimmune diseases
cancer
antibodies against
cxcl13
Prior art date
Application number
EA202092162A
Other languages
English (en)
Inventor
Хайцзюань Гу
Цюмэй Ян
Original Assignee
Ай-Маб Биофарма Юэс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ай-Маб Биофарма Юэс Лимитед filed Critical Ай-Маб Биофарма Юэс Лимитед
Publication of EA202092162A1 publication Critical patent/EA202092162A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предложены антитела или их фрагменты, обладающие специфичностью связывания белка хемокина с (C-X-C-мотивом)-лиганда 13 (CXCL13) человека. В различных примерах антитела или их фрагменты включают области CDR VH и VL, описанные в настоящем документе, или их варианты. Также предложены способы применения указанных антител или их фрагментов для лечения аутоиммунных заболеваний и нарушений.
EA202092162A 2018-09-18 2019-09-18 Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака EA202092162A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018106158 2018-09-18
PCT/CN2019/106409 WO2020057540A1 (en) 2018-09-18 2019-09-18 Anti-cxcl13 antibodies for treating autoimmune diseases and cancer

Publications (1)

Publication Number Publication Date
EA202092162A1 true EA202092162A1 (ru) 2021-07-01

Family

ID=69888374

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092162A EA202092162A1 (ru) 2018-09-18 2019-09-18 Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака

Country Status (14)

Country Link
US (2) US11028164B2 (ru)
EP (1) EP3713957A4 (ru)
JP (1) JP7098854B2 (ru)
KR (1) KR20200106056A (ru)
CN (1) CN112469735B (ru)
AU (2) AU2019342180B2 (ru)
BR (1) BR112021000583A2 (ru)
CA (1) CA3098509A1 (ru)
EA (1) EA202092162A1 (ru)
IL (1) IL281441B2 (ru)
MX (1) MX2021002605A (ru)
SG (1) SG11202010499UA (ru)
WO (1) WO2020057540A1 (ru)
ZA (1) ZA202100080B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230192824A1 (en) * 2020-04-02 2023-06-22 United States Of America As Represented By The Secretary Of The Navy Antigen Binding Proteins to Class 5 ETEC Adhesins
US20230348571A1 (en) * 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
CN116782930A (zh) 2020-06-11 2023-09-19 瓦西尼斯公司 Cxcl13结合分子促进周围神经再生的用途
US20240059762A1 (en) * 2020-12-18 2024-02-22 Single Cell Technology, Inc. Anti-sars coronavirus-2 nucleocapsid protein antibodies
WO2022182562A1 (en) * 2021-02-23 2022-09-01 BioLegend, Inc. ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS
CN113234137B (zh) * 2021-06-21 2022-02-25 华中农业大学 分离自草鱼的CXCL20a蛋白在作为抗菌肽中的应用
WO2023196588A2 (en) * 2022-04-08 2023-10-12 Beam Therapeutics Inc. Hemoglobin g-makassar binding polypeptides and antibodies and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512701B2 (en) * 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US7919083B2 (en) * 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
CA2501422C (en) * 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
RU2449808C2 (ru) * 2006-04-21 2012-05-10 Сентокор, Инк. Антагонисты cxcl13 и их применение для лечения воспалительных заболеваний
US20080227704A1 (en) * 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) * 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
JP6097690B2 (ja) * 2010-09-02 2017-03-15 ヴァクシネックス， インコーポレイテッド 抗ｃｘｃｌ１３抗体およびそれを用いる方法
NZ629828A (en) * 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
NZ710744A (en) * 2013-01-31 2020-07-31 Vaccinex Inc Methods for increasing immunoglobulin a levels
WO2014137355A1 (en) * 2013-03-08 2014-09-12 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences

Also Published As

Publication number Publication date
EP3713957A1 (en) 2020-09-30
CN112469735B (zh) 2022-11-08
ZA202100080B (en) 2022-06-29
IL281441A (en) 2021-04-29
IL281441B (en) 2022-10-01
KR20200106056A (ko) 2020-09-10
MX2021002605A (es) 2021-07-21
CN112469735A (zh) 2021-03-09
BR112021000583A2 (pt) 2021-04-06
WO2020057540A8 (en) 2020-07-23
JP2021513324A (ja) 2021-05-27
AU2019342180B2 (en) 2021-08-05
EP3713957A4 (en) 2021-08-18
WO2020057540A1 (en) 2020-03-26
US11028164B2 (en) 2021-06-08
JP7098854B2 (ja) 2022-07-12
IL281441B2 (en) 2023-02-01
SG11202010499UA (en) 2020-11-27
US20210284724A1 (en) 2021-09-16
AU2019342180A1 (en) 2020-07-16
CA3098509A1 (en) 2020-03-26
US20200399360A1 (en) 2020-12-24
AU2021261971A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
EA202092162A1 (ru) Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака
EA202190378A1 (ru) Антитела против ifnar1 для лечения аутоиммунных заболеваний
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
WO2019157366A8 (en) Antibody variable domains targeting the nkg2d receptor
CR20220578A (es) Anticuerpos de unión a cd3
MX2018016404A (es) Anticuerpos de union a cd3.
NZ756678A (en) Anti-lag-3 antibodies and uses thereof
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
MX2016011414A (es) Anticuerpos de proteina accesoria del receptor de interleucina-1 antihumana (il1 rap) y usos de los mismos.
MX2022003249A (es) Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso.
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA202092459A1 (ru) Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают
MX2021011715A (es) Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención.
MX2022005866A (es) Anticuerpos biparatopicos frente a cd73.
WO2020089396A3 (en) Composition and methods of treating inflammatory and autoimmune diseases
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
EA202192488A1 (ru) Антитела против tsg-6 и их применения